The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Atorvastatin Centrient 30 mg film-coated tablets

30 milligram(s) Film-coated tablet

Centrient Pharmaceuticals Netherlands B.VPA1832/005/003

Main Information

Trade NameAtorvastatin Centrient 30 mg film-coated tablets
Active SubstancesAtorvastatin
Strength30 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderCentrient Pharmaceuticals Netherlands B.V
Licence NumberPA1832/005/003

Group Information

ATC CodeC10AA HMG CoA reductase inhibitors
C10AA05 atorvastatin


Licence Issued20/10/2017
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0001-033-003
Interchangeable List DocumentPDF of Interchangeable List
« Back